Name | 2-(4-methoxyphenyl)-3-[4-(2-piperidin-1-ylethoxy)phenoxy]-1-benzothiophen-6-ol |
---|---|
Synonyms |
Arzoxifene
UNII-E569WG6E60 |
Description | Arzoxifene (LY353381) is an orally active selective estrogen receptor modulator with a fixed ring structure similar to raloxifene. Arzoxifene has minimal side effects with powerful antiestrogenic effects on breast cancer and endometrium, with equally strong favorable estrogenic effects on bone and lipid profile[1]. |
---|---|
Related Catalog | |
Target |
estrogen[1] |
In Vitro | Arzoxifene reduces estrogen receptor expression in endometrial cancer cell lines (ECC-1)[1]. |
In Vivo | Arzoxifene inhibits MCF-7 breast cancer xenograft growth in oophorectomized athymic mice. Arzoxifene is reported to prevent body weight increase in oophorectomized rats[1]. |
References |
Density | 1.234g/cm3 |
---|---|
Boiling Point | 656.4ºC at 760mmHg |
Molecular Formula | C28H29NO4S |
Molecular Weight | 475.59900 |
Flash Point | 350.8ºC |
Exact Mass | 475.18200 |
PSA | 79.40000 |
LogP | 6.87740 |
Vapour Pressure | 7.85E-18mmHg at 25°C |
Index of Refraction | 1.635 |